Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEXUCLUE 40 mg in Non-Erosive Reflux Disease
KCT0007562Phase 2Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexuprazan in Non-erosive Gastroesophageal Reflux Disease (NERD), sponsored by Daewoong Pharmaceutical. Started Oct 2022; status: terminated.
02
Drugs
fexuprazan
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on KCT0007562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007562.